Abstract PD17-12: Primary Efficacy and Safety Results from the AMALEE Trial Evaluating 600 Mg Vs 400 Mg Starting Doses of First-Line Ribociclib in Patients with HR+/HER2− Advanced Breast Cancer
Cancer research（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined